It is well known that there is a reduced level of adiponectin in patients with coronary atherosclerosis [42] as well as in the combination of CAD with obesity [43]; it was the establishment that adiponectin is an independent risk factor of coronary artery disease occurrence, but not its advancement [44]. Here, ADIPOQ is linked to coronary artery disorder.